2019nCoV
13
0
0
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
15.4%
2 terminated out of 13 trials
33.3%
-53.2% vs benchmark
31%
4 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (13)
Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection
Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
PHenotyping patiENts Admitted to Hospital With cOvid-19 Infection and idenTifYing Prognostic markErs
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia
Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients
Prognositc Factors in COVID-19 Patients Complicated With Hypertension
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children
The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia